Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2015-11-26

Clinical Trial Update: Safety, Tolerability and Efficacy Study of LiRIS® 400 mg in Women With Interstitial Cystitis [Phase 2]

View source ↗

Summary

A Phase 2 safety, tolerability and efficacy study of LiRIS 400 mg in women with interstitial cystitis was terminated, and results were posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • LiRIS 400 mg

Snippet

Sponsor: Allergan | Conditions: Interstitial Cystitis | Phase 2 | Status: TERMINATED | Results posted: 2015-11-26